2. GPCR/G Protein
  3. Guanylate Cyclase
  4. Cinaciguat

Cinaciguat  (Synonyms: BAY 58-2667)

Cat. No.: HY-14181 Purity: 99.20%
COA Handling Instructions

Cinaciguat is an activator of guanylate cyclase (sGC), and used for acute decompensated heart failure.

For research use only. We do not sell to patients.

Cinaciguat Chemical Structure

Cinaciguat Chemical Structure

CAS No. : 329773-35-5

Size Price Stock Quantity
Solution
10 mM * 1 mL in DMSO USD 224 In-stock
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
 USD 224 In-stock
Solid
2 mg USD 120 In-stock
5 mg USD 180 In-stock
10 mg USD 300 In-stock
50 mg USD 1080 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Cinaciguat:

Top Publications Citing Use of Products

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

Cinaciguat is an activator of guanylate cyclase (sGC), and used for acute decompensated heart failure.

In Vitro

Cinaciguat (10 μM) significantly enhances intracellular cGMP generation. Cinaciguat does not dose-dependent effects on cell contraction and calcium transients[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo

Cinaciguat (10 mg/kg/day, p.o.) treatment in diabetic rats does not influence blood glucose levels, but leads to attenuated water intake. Cinaciguat treatment alleviates diabetes mellitus related oxidative stress, protects against DM related alteration of the NO-sGC-cGMP-PKG signalling, and alleviates DM related myocardium hypertrophy and apoptosis[1]. Cinaciguat (1-10-100 nM) induces concentration-dependent relaxations in strips from both WT and apo-sGC mice, but does not have any effect on phasic activity induced by PGF2α in WT or apo-sGC strips[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
Molecular Weight

565.70

Appearance

Solid

Formula

C36H39NO5
CAS No.
SMILES

OC(C(C=C1)=CC=C1CN(CCCCC(O)=O)CCC(C=CC=C2)=C2OCC(C=C3)=CC=C3CCC4=CC=CC=C4)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 50 mg/mL (88.39 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.7677 mL 8.8386 mL 17.6772 mL
5 mM 0.3535 mL 1.7677 mL 3.5354 mL
10 mM 0.1768 mL 0.8839 mL 1.7677 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (4.42 mM); Suspended solution; Need ultrasonic

  • 2.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.42 mM); Clear solution

*All of the co-solvents are available by MCE.
Purity & Documentation

Purity: 99.20%

COA (247 KB) RP-HPLC (189 KB)

Handling Instructions (2659 KB)
References
Animal Administration
[1]

After confirmation of DM, rats are randomised into four groups: vehicle-treated control, cinaciguat-treated control, vehicle-treated diabetic and cinaciguat-treated diabetic groups. Animals are treated for 8 weeks with 0.5% methylcellulose vehicle or with the sGC activator cinaciguat in suspension p.o. (10 mg/kg/day), starting immeadiately after DM confirmation. Water bottles are filled every morning with the same amount of fresh tap water and daily water intake is measured. Animal cages are handled with care and are not moved after water bottle replacement to prevent spilling of water from the bottles. Body weight of the animals are recorded every 2 days and the dose of cinaciguat is adjusted accordingly.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

Cinaciguat329773-35-5BAY 58-2667Guanylate CyclaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Cinaciguat
Cat. No.:
HY-14181
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email address *

Phone number

 

Department *

Organization name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.